Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.60 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL28608401 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL11157243 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL30578900 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL106606 | 1.00 | — | — | |
| Maleic Acid SCHEMBL8163405 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL107031 | 1.00 | — | — | |
| Maleic Acid SCHEMBL7961962 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL263298 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL5799074 | 1.00 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL106604 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837273-B1 | IMPROVED PROTEIN RECOVERY | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | claimed |
| US-20210171573-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-10 | — | — | US | claimed |
| CN-112566920-A | Improved protein recovery | 百时美施贵宝公司 | 2021-03-26 | — | — | CN | claimed |
| WO-2025213238-A1 | ANTI-KMA ANTIBODY FORMULATIONS | HaemaLogiX Ltd (AU) | 2025-10-16 | — | — | WO | disclosed |
| EP-4511378-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | Carthronix, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024159069-A1 | ICOSAHEDRAL PHAGE DERIVED PARTICLES | GENSAIC, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-12043663-B2 | Anti-TNF-alpha-antibodies and functional fragments thereof | TILLOTTS PHARMA AG (CH) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151978-A1 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024152014-A1 | FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3456738-B1 | ANTIBODY VARIANTS | TILLOTTS PHARMA AG (CH) | 2024-07-17 | — | — | EP | disclosed |
| CN-118354789-A | Anti-glyco-cMET antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-1998028007-A1 | STABLE LIQUID INTERFERON FORMULATIONS | BIOGEN, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0386106-B1 | GAMMA INTERFERON FORMULATION | GENENTECH INC (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5151265-A | A stable liquid interferon solution | GENENTECH, INC. (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0386106-A1 | GAMMA INTERFERON FORMULATION. | GENENTECH INC (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004177-A1 | GAMMA INTERFERON FORMULATION | GENENTECH, INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0284249-A1 | Lyophilized lymphokine composition | INTERFERON SCIENCES, INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4675184-A | VIRICIDES | 501 Sunstar Kabushiki Kaisha (JP) | 1987-06-23 | — | — | US | disclosed |
| US-4605555-A | INTERFERON, POLYHYDRIC SUGAR ALCOHOL, ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| US-4605556-A | APPLYING INTERFERON, POLYHYDRIC SUGAR ALCOHOL, AND ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |